Roundtable Discussion; The Future of Mineral Sands. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksSKIN.L Regulatory News (SKIN)

  • There is currently no data for SKIN

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Form 8.3 - Integumen Plc

1 Sep 2020 12:05

Form 8.3 - Integumen Plc

FORM 8.3

PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY A PERSON WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORERule 8.3 of the Takeover Code (the “Code”)

1. KEY INFORMATION

(a) Full name of discloser:Investec Wealth & Investment
(b) Owner or controller of interests and short positions disclosed, if different from 1(a): The naming of nominee or vehicle companies is insufficient. For a trust, the trustee(s), settlor and beneficiaries must be named. N/A
(c) Name of offeror/offeree in relation to whose relevant securities this form relates: Use a separate form for each offeror/offeree Integumen plc
(d) If an exempt fund manager connected with an offeror/offeree, state this and specify identity of offeror/offeree:N/A
(e) Date position held/dealing undertaken: For an opening position disclosure, state the latest practicable date prior to the disclosure 28th August 2020
(f) In addition to the company in 1(c) above, is the discloser making disclosures in respect of any other party to the offer? If it is a cash offer or possible cash offer, state “N/A” Yes – Modern Water plc 1st September 2020

2. POSITIONS OF THE PERSON MAKING THE DISCLOSURE

If there are positions or rights to subscribe to disclose in more than one class of relevant securities of the offeror or offeree named in 1(c), copy table 2(a) or (b) (as appropriate) for each additional class of relevant security.

(a) Interests and short positions in the relevant securities of the offeror or offeree to which the disclosure relates following the dealing (if any)

Class of relevant security:  
InterestsShort positions
Number%Number%
(1) Relevant securities owned and/or controlled:26,812,0002.41%  
(2) Cash-settled derivatives:     
(3) Stock-settled derivatives (including options) and agreements to purchase/sell:    
TOTAL:26,812,0002.41%  

All interests and all short positions should be disclosed.

Details of any open stock-settled derivative positions (including traded options), or agreements to purchase or sell relevant securities, should be given on a Supplemental Form 8 (Open Positions).

(b) Rights to subscribe for new securities (including directors’ and other employee options)

Class of relevant security in relation to which subscription right exists: 
Details, including nature of the rights concerned and relevant percentages: 

3. DEALINGS (IF ANY) BY THE PERSON MAKING THE DISCLOSURE

Where there have been dealings in more than one class of relevant securities of the offeror or offeree named in 1(c), copy table 3(a), (b), (c) or (d) (as appropriate) for each additional class of relevant security dealt in.

The currency of all prices and other monetary amounts should be stated.

(a) Purchases and sales

Class of relevant securityPurchase/sale Number of securitiesPrice per unit
N/A – Opening Position Disclosure

(b) Cash-settled derivative transactions

Class of relevant securityProduct descriptione.g. CFDNature of dealinge.g. opening/closing a long/short position, increasing/reducing a long/short positionNumber of reference securitiesPrice per unit
     

(c) Stock-settled derivative transactions (including options)

(i) Writing, selling, purchasing or varying

Class of relevant securityProduct description e.g. call optionWriting, purchasing, selling, varying etc.Number of securities to which option relatesExercise price per unitTypee.g. American, European etc.Expiry dateOption money paid/ received per unit
        

(ii) Exercise

Class of relevant securityProduct descriptione.g. call optionExercising/ exercised againstNumber of securitiesExercise price per unit
    

(d) Other dealings (including subscribing for new securities)

Class of relevant securityNature of dealinge.g. subscription, conversionDetailsPrice per unit (if applicable)
    

4. OTHER INFORMATION

(a) Indemnity and other dealing arrangements

Details of any indemnity or option arrangement, or any agreement or understanding, formal or informal, relating to relevant securities which may be an inducement to deal or refrain from dealing entered into by the person making the disclosure and any party to the offer or any person acting in concert with a party to the offer:Irrevocable commitments and letters of intent should not be included. If there are no such agreements, arrangements or understandings, state “none”
N/A

(b) Agreements, arrangements or understandings relating to options or derivatives

Details of any agreement, arrangement or understanding, formal or informal, between the person making the disclosure and any other person relating to:(i) the voting rights of any relevant securities under any option; or (ii) the voting rights or future acquisition or disposal of any relevant securities to which any derivative is referenced:If there are no such agreements, arrangements or understandings, state “none”
N/A

(c) Attachments

Is a Supplemental Form 8 (Open Positions) attached?NO

Date of disclosure:1st September 2020
Contact name:Phil Beardwell Chartered FCSI
Telephone number:020 7597 1356

Public disclosures under Rule 8 of the Code must be made to a Regulatory Information Service and must also be emailed to the Takeover Panel at monitoring@disclosure.org.uk. The Panel’s Market Surveillance Unit is available for consultation in relation to the Code’s disclosure requirements on +44 (0)20 7638 0129.

The Code can be viewed on the Panel’s website at www.thetakeoverpanel.org.uk.

Date   Source Headline
2nd May 201910:51 amRNSHolding(s) in Company
2nd May 20198:18 amRNSBoard Appointment & Admission of Shares
1st May 201911:00 amRNSChanges to interests of a significant shareholder
30th Apr 20191:18 pmRNSResult of General Meeting
25th Apr 20197:01 amRNSTurner Pope Investor Evening
25th Apr 20197:00 amRNSLaunch of New Animal-Free Labskin Dandruff Test
12th Apr 20197:00 amRNSAcquisition of RinoCloud, Placing to raise £2.518m
25th Mar 20197:00 amRNSCBD tests boost procollagen and reduce irritation
21st Mar 20198:45 amRNSExercise of Warrants - Replacement
21st Mar 20197:01 amRNSExercise of Warrants
21st Mar 20197:00 amRNSLabskin:addl workspace at DHEZ Bradford University
18th Mar 20197:00 amRNSChange of Adviser
13th Mar 20194:35 pmRNSPrice Monitoring Extension
13th Mar 20197:00 amRNSExercise of Options
12th Mar 201910:51 amRNSShare Price Movement
11th Mar 20192:05 pmRNSSecond Price Monitoring Extn
11th Mar 20192:00 pmRNSPrice Monitoring Extension
5th Mar 20194:40 pmRNSSecond Price Monitoring Extn
5th Mar 20194:35 pmRNSPrice Monitoring Extension
5th Mar 20197:01 amRNSIssue of Equity
5th Mar 20197:00 amRNSAcqn of specialist equipment for Labskin's lab
25th Feb 20192:05 pmRNSSecond Price Monitoring Extn
25th Feb 20192:00 pmRNSPrice Monitoring Extension
22nd Feb 20192:05 pmRNSSecond Price Monitoring Extn
22nd Feb 20192:00 pmRNSPrice Monitoring Extension
21st Feb 201911:05 amRNSSecond Price Monitoring Extn
21st Feb 201911:00 amRNSPrice Monitoring Extension
20th Feb 20197:00 amRNSLabskin CBD tests
8th Feb 20197:00 amRNSRollout of Labskin AI Software as a Service begins
7th Feb 20197:00 amRNSChanges to interests of a significant shareholder
23rd Jan 20197:41 amRNSHolding(s) in Company
7th Jan 20197:00 amRNSTrading Update
18th Dec 20187:00 amRNSDivestment of TSPro GmbH
13th Dec 20187:00 amRNSLabskin-On-A-Chip
11th Dec 20181:20 pmRNSIssue of Equity
7th Dec 201812:46 pmRNSResult of Meeting
22nd Nov 20187:00 amRNSSubscription/ Placing to raise £355k, Notice of GM
15th Nov 20182:05 pmRNSSecond Price Monitoring Extn
15th Nov 20182:00 pmRNSPrice Monitoring Extension
15th Nov 20187:00 amRNSTrading Update
1st Nov 20187:00 amRNSCompletion of acq'n of interest in Cellulac plc
11th Oct 20187:00 amRNSUpdate on Placing and Subscription
27th Sep 20183:15 pmRNSUpdate :Placing&Subscription;Trading Announcement
20th Sep 20189:57 amRNSReplacement:legal demand; Placing and Subscription
19th Sep 20187:00 amRNSDetail of legal demand;Placing/Subscription update
17th Sep 20187:00 amRNSFirst laboratory-grown human-skin test service
29th Aug 20187:00 amRNSInterim Results
9th Aug 20184:34 pmRNSResult of AGM
3rd Aug 20183:22 pmRNSShare Purchase Agreement signed; Issue of shares
2nd Aug 20182:57 pmRNSResult of Meeting

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.